Compare FBGL & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBGL | MBAI |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.6M |
| IPO Year | N/A | N/A |
| Metric | FBGL | MBAI |
|---|---|---|
| Price | $1.09 | $1.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 7.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.31 |
| 52 Week High | $1.20 | $3.92 |
| Indicator | FBGL | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 44.34 |
| Support Level | $0.53 | $1.31 |
| Resistance Level | $1.14 | $1.85 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.05 | 38.47 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.